news & information

21 APR 2016

Opthea Phase 1 wet AMD Clinical Trial with OPT-302 Meets Primary Safety Objective

read more >>
30 MAR 2016

Opthea Completes Patient Enrolment for Phase 1 wet AMD Trial

read more >>
07 MAR 2016

Results of Extraordinary General Meeting

read more >>
13 nov 2015

Circadian/Opthea presentation at OIS 2015

read more >>
10 nov 2015

Circadian to Present at US Ophthalmology Innovation Summit

read more >>
04 Nov 2015

Notice of 2015 Annual General Meeting

read more >>
23 Oct 2015

Circadian to regain VEGFR-3 intellectual property license

read more >>
09 Jul 2015

Circadian Corporate Presentation - July 2015

read more >>
01 Jul 2015

Circadian Commences Wet AMD OPT-302 Clinical Trial

read more >>
15 Jun 2015

Circadian receives IND approval from FDA to initiate clinical trial of OPT-302 for wet AMD patients

read more >>
02 Jun 2015

Circadian's Partner Eli Lilly Presents IMC-3C5 Data at ASCO

read more >>
07 May 2015

OPT-302 Data Presented at Major Ophthalmology Conferences

read more >>
07 May 2015

ARVO 2015 Conference: OPT-302 in wet AMD

read more >>
16 Apr 2015

Circadian Shareholder Newsletter April 2015

read more >>
14 Apr 2015

World Congress on Angiogenesis 2015: Poster

read more >>
27 Feb 2015

Circadian Half Year Report and Accounts

read more >>
15 Feb 2015

Circadian Investor Presentation - February 2015

read more >>
13 Feb 2015

Bioshares - Circadian Briefing Report

read more >>
05 Dec 2014

Circadian Announces Formation of Clinical Advisory Board

read more >>
26 Nov 2014

Completion of Placement and Appendix 3B

read more >>
18 Nov 2014

Results of 2014 Annual General Meeting

read more >>
18 Nov 2014

CEO's presentation to Annual General Meeting

read more >>
18 Nov 2014

Chairman's Address to Annual General Meeting: Nov 18 2014

read more >>
18 Nov 2014

CEO Address: Annual General Meeting: Nov 18 2014

read more >>
18 Nov 2014

Chairman's address to Annual General Meeting

read more >>
06 Nov 2014

Completion of Rights Issue

read more >>
17 Oct 2014

Circadian Annual General Meeting 2014

read more >>
10 Oct 2014

Circadian Letter to Shareholders

read more >>
10 Oct 2014

Circadian Capital Raising Prospectus

read more >>
06 Oct 2014

CIR Appendix 3B

read more >>
06 Oct 2014

Circadian Investment Presentation

read more >>
06 Oct 2014

Circadian Investor Presentation - Oct 6 2014

read more >>
06 Oct 2014

ASX Funding Announcement

read more >>
01 Oct 2014

Trading Halt

read more >>
30 Sep 2014

Circadian Allowed Key Patent for VEGFR-3 Traps in the United States

read more >>
29 Aug 2014

Preliminary Final Report

read more >>
23 Jun 2014

Opthea Awarded Grant for OPT-302 Manufacture

read more >>
03 Jun 2014

Poster Presentation at ASCO

read more >>
02 Jun 2014

Circadian's VGX-100 Well Tolerated in Phase 1 Clinical Trial

read more >>
19 May 2014

Circadian Appoints CFO and Company Secretary

read more >>
15 May 2014

VGX-100 Phase 1 Study Selected for Presentation at ASCO 2014

read more >>
12 May 2014

Opthea Completes Pre-IND Meeting with FDA

read more >>
07 May 2014

Poster Presentation at ARVO

read more >>
06 May 2014

VEGF-C blockade with OPT-302 reduces established wet AMD lesions in the mouse

read more >>
29 Apr 2014

CEO Terms of Employment

read more >>
21 Feb 2014

Half Year Report & Accounts

read more >>
21 Feb 2014

Circadian Appoints CEO and Managing Director

read more >>
14 Jan 2014

Opthea signs cell line commercial license agreement with Selexis

read more >>
10 Dec 2013

Appendix 3Z - Final Directors Interest Notice

read more >>
06 Dec 2013

Appendix 3X - Initial Director’s Interest Notice

read more >>
03 Dec 2013

Circadian CEO and Board Changes

read more >>
29 Nov 2013

Results of Annual General Meeting

read more >>
29 Nov 2013

CEOs Address To Annual General Meeting

read more >>
29 Nov 2013

Chairmans Address To Annual General Meeting

read more >>
29 Nov 2013

Appendix 3Z - Final Directors Interest Notice

read more >>
29 Nov 2013

Director Resignation

read more >>
27 Nov 2013

Phase 1b oncology trial completed

read more >>
15 Nov 2013

Federal Government R&D Tax Incentive - Circadian To Receive Over $2.5m

read more >>
04 Nov 2013

The Association of Alternate VEGF Ligands with Resistance to Anti-VEGF Therapy in Metastatic Colorectal Cancer

read more >>
30 Oct 2013

Opthea Signs Manufacturing Agreement for Lead Product

read more >>
28 Oct 2013

Annual Report / Notice of AGM and Proxy

read more >>
17 Oct 2013

Phase 1a clinical oncology trial with VGX-100 update

read more >>
01 Oct 2013

Revised AGM details

read more >>
11 Sep 2013

Analyst Investment Report on Circadian Website

read more >>
10 Sep 2013

New Company Secretary

read more >>
28 Aug 2013

Open Briefing

read more >>
28 Aug 2013

2012/13 Preliminary Annual Results

read more >>
15 Jul 2013

Circadian moves to new South Yarra office

read more >>
15 Jul 2013

The FDA has taken the first step in approving VEGF-D diagnostics as a test to monitor LAM

read more >>
02 Jul 2013

FDA grants humanitarian use device designation to VEGF-D kit

read more >>
17 Jun 2013

US Patent Granted Covering use of VEGFR-3

read more >>
04 Jun 2013

VGX-100 Phase 1 Oncology Trial Presented at ASCO 2013

read more >>
04 Jun 2013

VGX-100 Poster Presentation at ASCO

read more >>
27 May 2013

Change of Director’s Interest Notice

read more >>
24 May 2013

Open Briefing: VGX-300 Potential in AMD

read more >>
23 May 2013

Change of Director’s Interest Notice

read more >>
20 May 2013

Change of Director’s Interest Notice

read more >>
17 May 2013

Progress of VGX-100 Phase 1 trial to be presented at ASCO

read more >>
09 May 2013

VEGF-C shown to have major role in Age-Related Macular Degeneration (AMD)

read more >>
08 Mar 2013

Circadian grants world-wide licence to Santa Cruz Biotechnology Inc

read more >>
06 Mar 2013

Edison Research publishes updated analysis on Circadian. Values the company at $1.93/share

read more >>
27 Feb 2013

Circadian commences worldwide marketing & sales of unique VEGF-C & VEGF-D products as research reagents

read more >>
25 Feb 2013

Open Briefing: Interview with CEO & MD Robert Klupacs on H1 Results & Outlook

read more >>
22 Feb 2013

Appointment of CFO and Company Secretary

read more >>
20 Feb 2013

Resignation of CFO and Company Secretary

read more >>
18 Feb 2013

Half Year Report & Accounts

read more >>
07 Feb 2013

R&D Tax Incentive - Circadian Receives $1.3m

read more >>
04 Feb 2013

VGX-100 Phase 1 Clinical Trial Program Update

read more >>
10 Jan 2013

Company Presentation at JP Morgan Biotech Showcase

read more >>
17 Dec 2012

Change of Director’s Interest Notice

read more >>
11 Dec 2012

Open Briefing interview with MD & CEO Robert Klupacs

read more >>
21 Nov 2012

Change of Director's Interest Notice

read more >>
21 Nov 2012

Appendix 3B

read more >>
20 Nov 2012

Results of Annual General Meeting 20 November 2012

read more >>
20 Nov 2012

CEO AGM Presentation to shareholders

read more >>
20 Nov 2012

Chairman's Address to Shareholders

read more >>
20 Nov 2012

CEO AGM Presentation to Shareholders

read more >>
15 Nov 2012

Circadian grants world-wide licence to Bio-Rad to market research products

read more >>
08 Nov 2012

VGX-100 Poster Presentation at EORTC

read more >>
08 Nov 2012

VGX-100 Poster Presentation at EORTC

read more >>
07 Nov 2012

VGX-100 Top 10 Oncology Candidate Windhover Conference

read more >>
02 Nov 2012

AusBiotech Presentation Company Update

read more >>
22 Oct 2012

Annual Report / Notice of AGM and Proxy

read more >>
02 Oct 2012

Dr Errol Malta – Resignation as Director

read more >>
24 Sep 2012

Open Briefing - FY2012 Results and Outlook

read more >>
24 Aug 2012

Appendix 3B

read more >>
24 Aug 2012

Notice under section 708A(5)(e) of the Corporations Act 2001 (Cth)

read more >>
23 Aug 2012

Preliminary Final Report (Appendix 4E) - Financial Year Ended 30 June 2012

read more >>
17 Jul 2012

Update to Substantial Holding Notice for Antisense Therapeutics Limited

read more >>
12 Jul 2012

Change of Director’s Interest Notice

read more >>
10 Jul 2012

Change of Director’s Interest Notice

read more >>
09 Jul 2012

Alpha Securities Analyst Investment Research Report Available on Circadian Website

read more >>
07 Jul 2012

Bio 2012 - Building a Diagnostics Franchise

read more >>
27 Jun 2012

Commercial Launch of CUP Test

read more >>
22 Jun 2012

Appendix 3B

read more >>
22 Jun 2012

Notice under section 708A(5)(e) of the Corporations Act 2001 (Cth)

read more >>
12 Jun 2012

Circadian makes $1M Share Placement

read more >>
12 Jun 2012

Reinstatement to Official Quotation

read more >>
07 Jun 2012

Suspension Confirm

read more >>
07 Jun 2012

Suspension Request

read more >>
05 Jun 2012

Request for Trading Halt

read more >>
01 Jun 2012

Updated Corporate Presentation

read more >>
16 May 2012

Appendix 3B

read more >>
27 Apr 2012

Notice of Ceasing to be a Substantial Holder

read more >>
02 Apr 2012

Change of Director’s Interest Notice

read more >>
29 Mar 2012

Update to Substantial Holding Notice for Antisense Therapeutics Limited

read more >>
15 Mar 2012

Analyst Investment Research Report Available on Circadian Website

read more >>
09 Mar 2012

Positive data published on performance of Circadian’s Cancers of Unknown Primary Diagnostic Test

read more >>
09 Mar 2012

Development of a Gene Expression Based Assay to Determine the Origin of Metastatic Carcinomas of Unknown Primary

read more >>
20 Feb 2012

Open Briefing with CEO & MD Robert Klupacs - Half Year Results and Outlook

read more >>
16 Feb 2012

Half-Year Financial Report & Operational Achievements

read more >>
30 Jan 2012

VGX-100 identified as potential new therapy for improving corneal graft survival

read more >>
12 Jan 2012

CEO Presentation at Biotech Showcase San Francisco

read more >>
09 Jan 2012

Circadian commences first Phase 1 clinical trial of VEGF-C antibody VGX-100 in cancer patients

read more >>
21 Dec 2011

Change of Director’s Interest Notice

read more >>
19 Dec 2011

Finance News Network Interview with CEO Available on Circadian Website

read more >>
13 Dec 2011

Change of Director’s Interest Notice

read more >>
25 Nov 2011

Final Director’s Interest Notice

read more >>
24 Nov 2011

Results of Annual General Meeting 24 November 2011

read more >>
24 Nov 2011

Annual General Meeting Presentation 24 November 2011

read more >>
24 Nov 2011

Annual General Meeting Presentation 24 November 2011

read more >>
24 Nov 2011

Chairman's Address to Annual General Meeting 24 November 2011

read more >>
15 Nov 2011

Open Briefing with CEO & MD Robert Klupacs: CEO on IND status for VGX-100

read more >>
31 Oct 2011

Circadian receives FDA IND approval to begin clinical trials with VGX-100 for the treatment of cancer patients with solid tumors

read more >>
25 Oct 2011

Change of Director's Interest Notice

read more >>
24 Oct 2011

Notice of Annual General Meeting and Explanatory Memorandum

read more >>
20 Oct 2011

Change of Director's Interest Notice

read more >>
18 Oct 2011

Final Director's Interest Notice

read more >>
11 Oct 2011

Analyst Investment Research Reports Available on Circadian Website

read more >>
11 Oct 2011

Biopartnering Europe Presentation

read more >>
10 Oct 2011

Healthscope commences clinical validation study of Circadian's Cancer Diagnostic

read more >>
03 Oct 2011

Retirements from Circadian Board of Directors

read more >>
30 Sep 2011

Circadian files IND with FDA for VGX-100 for the treatment of cancer patients with solid tumors

read more >>
15 Sep 2011

Open Briefing with CEO & MD Robert Klupacs: FY12 Outlook and VGX-100 Progress

read more >>
13 Sep 2011

VGX-100 identified as potential new therapy for Dry Eye Disease

read more >>
12 Sep 2011

Circadian makes key appointment in clinical trials management

read more >>
11 Sep 2011

VEGFR-3 controls tip to stalk conversion at vessel fusion sites by reinforcing Notch signalling

read more >>
09 Sep 2011

Change of Director's Interest Notice

read more >>
07 Sep 2011

Change of Director's Interest Notice

read more >>
07 Sep 2011

Change of Director's Interest Notice

read more >>
07 Sep 2011

Circadian Corporate Presentation - Septemeber 2011

read more >>
06 Sep 2011

Change of Director's Interest Notice

read more >>
31 Aug 2011

Change in Substantial Holding for Optiscan Imaging Limited - Update

read more >>
31 Aug 2011

Change of Director's Interest Notice

read more >>
30 Aug 2011

Change of Director's Interest Notice

read more >>
24 Aug 2011

Preliminary Final Report Appendix 4E Financial Year Ended 30 June 2011

read more >>
25 Jul 2011

Change of Director's Interest Notice

read more >>
18 Jul 2011

Change of Directors Interest Notice

read more >>
14 Jul 2011

Open Briefing with CEO & MD Robert Klupacs

read more >>
16 Jun 2011

Circadian provides market update on clinical development plans for VGX-100 in oncology and eye disease indications

read more >>
16 Jun 2011

Circadian provides market update on clinical development plans for VGX-100 in oncology and eye disease indications

read more >>
14 Jun 2011

Circadian launches Level 1 ADR program and OTCQX Quotation in US

read more >>
10 Jun 2011

Substantial Holding Notice for Antisense Therapeutics Limited

read more >>
07 Jun 2011

VEGF-C and VEGF-D identified as biomarkers for Avastin resistance in colorectal cancer patients

read more >>
07 Jun 2011

VEGF-C and VEGF-D identified as biomarkers for Avastin resistance in colorectal cancer patients

read more >>
30 May 2011

Analyst Investment Research Reports Available on Circadian Website

read more >>
18 Apr 2011

Circadian Technologies (Small Cap Showcase 2011) - Robert Klupacs Presentation

read more >>
07 Apr 2011

Open Briefing with CEO & MD Robert Klupacs on First Phase I Clinical Trial of IMC - 3C5

read more >>
06 Apr 2011

Circadian's VGX-100 Inhibits Tumour Growth in Models of Lung, Ovarian and Prostate Cancer

read more >>
06 Apr 2011

Circadian's partner ImClone Systems commences first Phase 1 clinical trial of VEGFR-3 antibody IMC-3C5

read more >>
02 Apr 2011

The novel therapeutic monoclonal antibody VGX-100 neutralises VEGF-C and inhibits tumor growth and metastasis in subcutaneous and orthotopic models of human cancer

read more >>
22 Mar 2011

New issue announcement, application for quotation of additional securities and agreement

read more >>
15 Feb 2011

31 December 2010 Half-Year Financial Report & Operational Achievements

read more >>
14 Feb 2011

Finance News Network Interview with Circadian CEO Robert Klupacs

read more >>
02 Feb 2011

Circadian Launches First Diagnostic for LAM Lung Disease with U.S. Partner

read more >>
17 Jan 2011

VEGF-D Licence Agreement Open Briefing

read more >>
13 Jan 2011

Chugai Pharmaceutical of Japan Grants Circadian Worldwide Licence to its VEGF-D Intellectual Property Estate

read more >>
11 Jan 2011

2011 Biotech Showcase

read more >>
16 Dec 2010

Securities Trading Policy

read more >>
15 Dec 2010

Substantial Holding Notice for Antisense Therapeutics Limited

read more >>
19 Nov 2010

Change of Directors Interest Notice

read more >>
18 Nov 2010

Open Briefing - VEGF Inhibitor Technology Patents

read more >>
18 Nov 2010

Circadian Technologies Limited Sale of Unmarketable Parcels Complete

read more >>
11 Nov 2010

2010 AGM Managing Director's Presentation

read more >>
11 Nov 2010

Results of Annual General Meeting 11 November 2010

read more >>
10 Nov 2010

Major US and European Patents Granted to Circadian

read more >>
14 Oct 2010

Open Briefing - CEO on FY11 LAM Diagnostic Partnership

read more >>
11 Oct 2010

Notice of Annual General Meeting and Explanatory Memorandum

read more >>
11 Oct 2010

2010 Annual Report

read more >>
05 Oct 2010

Finance News Network Video Interview with CEO (CIR)

read more >>
30 Sep 2010

Circadian partners with Cincinnati Childrens Hospital in U.S. to develop blood test diagnostic for potentially fatal lung disease

read more >>
17 Sep 2010

Circadian Technologies Limited to Offer Shareholder Sale Facility for Unmarketable Parcels

read more >>
09 Sep 2010

Open Briefing - CEO on FY11 Outlook and Strategic Focus

read more >>
06 Sep 2010

Circadian granted key strategic VEGF-D patent in USA for diagnostic applications

read more >>
25 Aug 2010

Change of Directors Interest Notice

read more >>
20 Aug 2010

Preliminary Final Report (Appendix 4E) Financial Year Ended 30 June 2010

read more >>
18 Aug 2010

Notice of Change of Interests of Substantial Holder

read more >>
18 Aug 2010

Notice of Change of Interests of Substantial Holder

read more >>
16 Aug 2010

New issue announcement, application for quotation of additional securities and agreement

read more >>
16 Aug 2010

Details of the issue or offer of securities

read more >>
03 Aug 2010

Australian Microcap Investment Conference Presentation

read more >>
30 Jul 2010

Shares to be released from escrow

read more >>
28 Jun 2010

Corporate Presentation

read more >>
14 May 2010

Change of Directors Interest Notice

read more >>
13 May 2010

Change of Directors Interest Notice

read more >>
13 May 2010

Change of Directors Interest Notice

read more >>
13 May 2010

Ms Susan Madden appointed Company Secretary of Circadian

read more >>
11 May 2010

Change of Directors Interest Notice

read more >>
04 May 2010

VGX-100 Inhibits Tumour Growth - Open Briefing with CEO & MD Robert Klupacs

read more >>
30 Apr 2010

Change of Directors Interest Notice

read more >>
17 Apr 2010

VGX-100, a novel therapeutic monoclonal antibody targeting VEGF-C that inhibits tumor growth

read more >>
15 Apr 2010

VGX-100 significantly inhibits tumour growth in animal cancer models

read more >>
15 Apr 2010

Ms Natalie Korchev to resign as CFO and Company Secretary

read more >>
06 Apr 2010

Circadian Newsletter - April 2010

read more >>
26 Mar 2010

Change in substantial holding

read more >>
24 Mar 2010

Corporate Presentation

read more >>
24 Mar 2010

Current Corporate Presentation

read more >>
17 Feb 2010

Half Year Results and Operational Achievements

read more >>
05 Feb 2010

Change in substantial holder

read more >>
22 Dec 2009

Commencement of Circadian non-executive director share plan

read more >>
07 Dec 2009

Circadian and CSIRO enter strategic research alliance

read more >>
19 Nov 2009

2009 AGM Managing Director's Presentation

read more >>
19 Nov 2009

2009 AGM Managing Director's Presentation

read more >>
19 Nov 2009

Results of Annual General Meeting

read more >>
10 Nov 2009

Merriman Presentation

read more >>
10 Nov 2009

CIR to present at Merriman Curhan Ford's US Investor Summit

read more >>
29 Oct 2009

Circadian subsidiary terminates licence to Ark Therapeutics

read more >>
16 Oct 2009

Open Briefing - CEO on Manufacturing Milestone and Update

read more >>
14 Oct 2009

Notice of Annual General Meeting

read more >>
14 Oct 2009

2009 Annual Report

read more >>
13 Oct 2009

Manuafacturing milestone achieved for cancer drug candidate VGX-300

read more >>
14 Sep 2009

Change of date for Circadian's 2009 AGM

read more >>
09 Sep 2009

Change of Director's Interest Notice - Robert Klupacs

read more >>
08 Sep 2009

Change in substantial holder

read more >>
07 Sep 2009

Circadian provides PerkinElmer with worldwide rights to market research products

read more >>
03 Sep 2009

Circadian Newsletter - September 2009

read more >>
25 Aug 2009

Initial Director's Interest Notice - Dr Errol Malta

read more >>
25 Aug 2009

Circadian granted key VEGF-C patent in Japan

read more >>
20 Aug 2009

Preliminary final report

read more >>
20 Aug 2009

Dr Errol Malta appointed non-executive director

read more >>
30 Jul 2009

Shares to be released from escrow

read more >>
09 Jul 2009

Corporate Presentation

read more >>
09 Jul 2009

Corporate Presentation

read more >>
30 Jun 2009

Appendix 3B - Employee incentive

read more >>
18 Jun 2009

Circadian granted key strategic VEGF-D patent in Europe for angiogenic applications

read more >>
03 Jun 2009

Circadian sponsors international conference on angiogenesis research

read more >>
22 May 2009

Circadian licensee Ark Therapeutics announces Trinam phase III study enrols first patient

read more >>
19 May 2009

Open Briefing - CEO on Recent Achievements

read more >>
13 May 2009

FINSIA Presentation

read more >>
13 May 2009

FINSIA presentation - "The Survivors: strong business and balance sheet"

read more >>
06 May 2009

Circadian Scientific Advisory Board Chairman, Prof. Kari Alitalo, wins prestigious award for biomedical research

read more >>
24 Apr 2009

BioMelbourne Network Presentation

read more >>
24 Apr 2009

Change of Director's Interest Notice - Dominique Fisher

read more >>
24 Apr 2009

BioMelbourne Network presentation - Transformation of Circadian

read more >>
22 Apr 2009

Circadian partner ImClone Systems demonstrates VEGFR-3 antibody improves anti-tumour effects of chemotherapy in mouse tumour models

read more >>
02 Apr 2009

Circadian Newsletter - April 2009

read more >>
26 Mar 2009

Corporate Presentation

read more >>
26 Mar 2009

Corporate Presentation

read more >>
02 Mar 2009

Open Briefing on Cancer Diagnostic Commercialisation

read more >>
25 Feb 2009

Circadian and Healthscope to commercialise Peter Mac Cancer Diagnostic

read more >>
09 Feb 2009

Half-Year Results & Operational Achievements

read more >>
22 Jan 2009

Open Briefing - CEO on Trinam Phase III Trial

read more >>
09 Jan 2009

Ark Therapeutics receives clearance to commence Phase 3 trial of Trinam

read more >>
14 Nov 2008

Managing Director's AGM Presentation

read more >>
21 Oct 2008

Corporate Presentation

read more >>
16 Oct 2008

Wilson HTM Life Sciences Showcase

read more >>
25 Jun 2008

Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation

read more >>
04 Jan 2008

Change of Directors Interest Notice

read more >>
04 Jan 2008

Change of Directors Interest Notice

read more >>
02 Jan 2008

Change of Directors Interest Notice

read more >>
11 Dec 2007

Change in Substantial Holding

read more >>
03 Dec 2007

Leon Serry, Managing Director of Circadian, announces retirement effective 1 March 2008, Robert Klupacs appointed CEO elect

read more >>
25 Oct 2007

Results of AGM

read more >>
25 Oct 2007

Resignation as a director - Graeme Kaufman

read more >>
25 Oct 2007

Final director's interest notice

read more >>
24 Oct 2007

Presentations to AGM

read more >>
21 Sep 2007

Annual report and notice of AGM

read more >>
13 Sep 2007

Change of registered office address

read more >>
21 Aug 2007

Becoming a substantial holder

read more >>
14 Aug 2007

Preliminary final report

read more >>
31 Jul 2007

Change in substantial holding

read more >>
14 Jul 2007

Trading halt

read more >>
29 Jun 2007

Vegenics & Sienagen to exploit VEGF-D in bone disease

read more >>
18 Jun 2007

Vegenics further extends VEGF-C intellectual property

read more >>
23 May 2007

Vegenics licensee announces early trial clearance

read more >>
09 May 2007

Ceasing to be a substantial holder for AVX

read more >>
30 Apr 2007

Circadian to present at US investor forums

read more >>
27 Apr 2007

Notice of initial substantial holder - AVX

read more >>
18 Apr 2007

Change in substantial holding for OIL

read more >>
13 Apr 2007

Licences novated to Vegenics

read more >>
02 Apr 2007

Vegenics completes capital raising

read more >>
29 Mar 2007

Change in substantial holding for AVX

read more >>
29 Mar 2007

Ceasing to be a substantial holder for AVX

read more >>
22 Mar 2007

Appendix 3B Employee incentive

read more >>
27 Feb 2007

Antibody development collaboration with EvoGenix

read more >>
13 Feb 2007

Half yearly report and accounts

read more >>
13 Feb 2007

Appendix 3B Employee incentive

read more >>
05 Feb 2007

Change in substantial holding for AVX

read more >>
31 Jan 2007

Results of General Meeting

read more >>
24 Jan 2007

Change in substantial holding for AVX

read more >>
19 Jan 2007

Additional investment in Vegenics

read more >>
19 Jan 2007

ASX listed shareholdings update

read more >>
12 Jan 2007

Change in substantial holding for AVX

read more >>
12 Jan 2007

Change in substantial holding for MBP

read more >>
11 Jan 2007

Becoming a substantial holder

read more >>
28 Dec 2006

Notice of General Meeting

read more >>
01 Dec 2006

ASX listed shareholdings update

read more >>
30 Nov 2006

Change in substantial holding for MBP

read more >>
21 Nov 2006

Appendix 3Y Change of director's interest

read more >>
15 Nov 2006

Change in substantial holding for ANP

read more >>
13 Nov 2006

Change in substantial holding for AVX

read more >>
27 Oct 2006

Results of AGM

read more >>
27 Oct 2006

Executive long-term incentives

read more >>
26 Oct 2006

Presentations to AGM

read more >>
25 Oct 2006

Amended change in substantial holding for ANP

read more >>
11 Oct 2006

Award of grant for conotoxin development

read more >>
22 Sep 2006

Annual report and notice of AGM

read more >>
21 Sep 2006

Additional investment in Vegenics

read more >>
28 Aug 2006

Preliminary final report

read more >>
22 Aug 2006

Vegenics announces agreement with CoGenesys

read more >>
17 Jul 2006

Resume trading

read more >>
10 Jul 2006

Grant for cancer vaccine development

read more >>
30 Jun 2006

Completion of due diligence on Ludwig project

read more >>
15 Jun 2006

Extension to collaboration with University of Sydney

read more >>
17 May 2006

Change in substantial holding for AVX

read more >>
02 May 2006

Presentation on Vegenics cancer project

read more >>
01 May 2006

Major cancer development agreement

read more >>
27 Apr 2006

Trading halt

read more >>
11 Apr 2006

Change in substantial holding for ANP

read more >>
31 Mar 2006

New research project

read more >>
31 Mar 2006

ASX listed shareholdings update

read more >>
10 Feb 2006

Half yearly report and accounts

read more >>
01 Aug 2005

Inhibition of Lymphogenous Metastasis Using Adeno-Associated Virus-Mediated Gene Transfer of a Soluble VEGFR-3 Decoy Receptor

read more >>
01 Feb 2005

Half yearly report and accounts

read more >>
14 Jan 2004

Appendix 3Y Change of director's interest

read more >>
29 Jan 2003

Appendix 4B Half yearly report and review of operations

read more >>
05 Jun 2002

Suppression of Tumor Lymphangiogenesis and Lymph Node Metastasis by Blocking Vascular Endothelial Growth Factor Receptor 3 Signaling

read more >>
04 Jan 2002

Initial director's interest notice x 5

read more >>
30 Jan 2001

Appendix 4B Half yearly report and review of operations

read more >>